George Knight
Family · Cincinnati, OHNPI 1144271180
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $108,010 of the $130,290 with a category attached, or 82.9%. Otsuka America Pharmaceutical, Inc. accounts for 99.7% of it on its own, with 11 other manufacturers making up the rest. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $407.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$130K
- Bayer$118
- Urovant Sciences Inc$98
- Otsuka Pharmaceutical Development & Commercialization, Inc.$71
- Sumitomo Pharma America, Inc.$23
- Acadia Pharmaceuticals Inc$19
- plus $82 from 6 others
What the payments were for
- Speaking & faculty fees$108,01083%
- Travel & lodging$16,97613%
- Food & beverage$5,3054%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 307 | $129,880 |
| Bayer | 1 | $118 |
| Urovant Sciences Inc | 1 | $98 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $71 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $14 |
| Novartis | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| Inogen, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$130,290 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 272 | $182,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $81,899 |
| RexultiBrexpiprazole | 59 | $66,308 |
| JardianceEmpagliflozin | 80 | $49,357 |
| XareltoRivaroxaban | 63 | $39,036 |
| TrulicityDulaglutide | 39 | $37,867 |
| LinzessLinaclotide | 38 | $24,486 |
| OzempicSemaglutide | 22 | $21,626 |
| EntrestoSacubitril/Valsartan | 31 | $13,258 |
| MyrbetriqMirabegron | 38 | $12,922 |
| TradjentaLinagliptin | 23 | $12,032 |
| JanuviaSitagliptin Phosphate | 24 | $11,456 |
| Divalproex Sodium | 44 | $10,895 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,665 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $10,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $129,880 | $66,30859 claims |
| Johnson & JohnsonXarelto | $12 | $39,03663 claims |
| NovartisEntresto | $12 | $13,25831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Cincinnati
- Jillian HuntCincinnati$116K
- Lindsey SpencerCincinnati$53K
- Bria BarjucaCincinnati$38K
- Jillian CowanCincinnati$20K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.